ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral
Generics BulletinIn the latest in a long line of legal decisions, Teva and Viatris have once again failed in their bid to knock out a key US patent shielding Janssen’s Invega Sustenna (paliperidone palmitate) once-mon
Generics BulletinThe full panel of the US Court of Appeals for the Federal Circuit will not review a decision which affirmed that Viatris’ proposed ANDA label for its generic version of Janssen’s Invega Trinza (palipe
Generics BulletinViatris emerged victorious at the June meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use, picking up a pair of positive opinions for new generic medicines, incl